|
Remicade - Infliximab reduces signs and symptoms of rheumatoid arthritis (RA) and prevents joint damage. It has also been shown to improve the physical function of joints, thus enabling RA sufferers to have an increased quality of life.
Clinical trials of large numbers of patients have shown on X-rays that infliximab slows down the progression of rheumatoid arthritis. With Remicade, there is a treatment that significantly reduces the joint damage caused by rheumatoid arthritis and returns sufferers to a more normal, daily routine. These are main treatment goals in this insidious disease and at present, those with severe disease are most likely to benefit from this medication.
Also, phase 3 trials conducted on Remicade (infliximab) showed rapid, significant improvement in patients with moderate to severe plaque psoriasis. The stud mainly used dose-ranging from 3 mg/kg and 5 mg/kg. The continuous eight week maintenance therapy resulted in greater long-term skin clearance compared with as-needed therapy regimens within each dose.
At 10 weeks it was seen that 70% of the patients treated with remicade 3 mg/kg and 75% of patients receiving 5 mg/kg achieved at least 75% improvement in psoriasis. At the end of the 50 weeks patients receiving remicade 5 mg/kg every eight-week maintenance therapy saw the highest level of improvement.
|
